NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 97

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

302069

Licensee	
1. Detroit Osteopathic Hospital Corporation Central Offices	In accordance with letter dated November 18, 1996
2. 26100 American Drive P.O. Box 5153 Southfield, MI 48086-5153	3. License Number 21-04082-01 is amended in its entirety to read as follows:
	4. Expiration Date November 30, 2000
	5. Docket or Reference No. 030-02042

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed
D. Any byproduct material identified in 10 CFR 35.500	D. Sealed sources identified in 10 CFR 35.500	D. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300.

D. For storage only.

9/

COPY

050088

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
21-04082-01

Docket or Reference Number
030-02042

Amendment No. 97

CONDITIONS

10. Locations of Use:

A. Bi-County Community Hospital
13355 East Ten Mile Rd.
Warren, MI

B. Riverside Osteopathic Hospital
150 Truax
Trenton, MI

11. Radiation Safety Officer: Richard P. Nelson, CNMT

12. Authorized User(s):

A. Amy Tobin, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

B. Malcolm E. Williamson, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

C. George J. Leach, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

D. Michael D. DeMattia, D.O., for material in 10 CFR 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).

E. Nancy J. Andrews, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

F. Paul Garber, D.O., for material in 10 CFR 35.100 and 35.200.

G. Karla Volke, D.O., for material in 10 CFR 35.100 and 35.200.

H. Dennis Vollman, D.O., for material in 10 CFR 35.100 and 35.200.

I. Peter J. Moorton, D.O., for material in 35.100 and 35.200.

J. Eric S. Langer, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

K. John R. Sutton, D.O., for material in 10 CFR 35.100, 35.200 and 35.300.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
21-04082-01

Docket or Reference Number
030-02042

Amendment No. 97

14. The licensee shall maintain records of information important to safe and effective decommissioning at 12523 Third Avenue, Highland Park, Michigan per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

15. This license is based on the licensee's statements and representations listed below:

A. Application dated September 10, 1990;

B. Letters dated September 13, 1990, November 27, 1992, January 8, 1993, April 5, 1993, July 27, 1995, and July 28, 1995;

C. Letters dated October 11, 1993 (with attachments), December 3, 1993, November 25, 1994, February 24, 1995 (excluding the Quality Management Program), and November 18, 1996 (with enclosures); and

D. Application dated December 3, 1993 except ALARA program.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date January 16, 1997

By Louis J. Howell
Nuclear Materials Licensing Branch, Region III

COPY

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C 2B
Exp. Date: 20001130
Fee Comments:
Decom Fin Assur Reqd: N

R8

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: DETROIT OSTEOPATHIC HOSPITAL CORP.
   Received Date: 961122
   Docket No: 3002042
   Control No.: 302069
   License No.: 21-04082-01
   Action Type: Amendment

2. FEE ATTACHED
   Amount: 440
   Check No.: 060160

3. COMMENTS

Signed D. Hersey
Date 11-22-96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / V)

1. Fee Category and Amount: 7C 2B #440

2. Correct Fee Paid. Application may be processed for:
   Amendment ✓
   Renewal
   License

3. OTHER

Signed JC
Date

1996 NOV 27 AM 8:49

DEC 02 1996

Log NOV 12 III
Remitter
Check No. 60160
Amount #440
Fee Category 7C 2B
Type of Fee AMD
Date Check Rec'd 11/27/96
Date Completed 11/29/96
By: JC

HORIZON HEALTH SYSTEM

HORIZON HEALTH SYSTEM

CORPORATE OFFICES
26100 American Drive
P.O. Box 5153
Southfield, Michigan 48086-5153
(810) 746-4300

Bi-County Community Hospital (Osteopathic) Warren, Michigan

Riverside Osteopathic Hospital Trenton, Michigan

Bi-County Outpatient Counseling Center Warren, Michigan

Centrum Insurance Co., Ltd.

Focus Health Care Horizon Home Care Pontiac, Michigan Trenton, Michigan Warren, Michigan

Hamtramck Health Center Hamtramck, Michigan

Horizon Center for Clinical Research

Horizon Dialysis Center Highland Park, Michigan

Horizon Family Medical Center Taylor, Michigan

Horizon Medical Associates, P.C.

Riverside Downriver Back Institute Trenton, Michigan

Schoenherr Physical Therapy Center Warren, Michigan

St. John Dialysis Center

Vista Resources, Inc. Vista Pharmacies, Inc. Vista Health Services

Affiliated with Michigan State University College of Osteopathic Medicine

Affiliated with Henry Ford Health System

November 18, 1996

RETURN RECEIPT REQUESTED
Certified Mail #P432161176

Materials Licensing Branch
U.S. Nuclear Regulatory Commission
Region III
801 Warrenville Road
Lisle, Il 60532-4351

Re: Amendment to NRC License #21-04082-01

Dear Sir:

We wish to amend our material's license #21-04082-01 as follows:

Authorized Radioactive Material

Please delete: 10 CFR 35.400, Depleted ^{235}U shielding and ^{137}Cs survey meter calibration source.
The material noted above has been transferred to another authorized users or disposed of through ADCO as a licensed NRC disposal firm.

Change: 10 CFR 35.500 authorized use to storage only.

Authorized Users

Delete: Arthur Levine, D.O., Richard Taras, D.O., and Ronald C. Lutsic, D.O. as authoirzed users as they are no longer actively involved with our program.

Add: Amy Tobin, D.O. for 10 CFR 35.100, 35.200 and 35.300

Paul Garber, D.O. for 10 CFR 35.100 and 35.200.

Karla Volke, D.O. for 10 CFR 35.100 and 35.200.

Training and experience for Dr Tobin is enclosed for your review. Dr. Garber is an authorized user on license #21-03835-01 and Dr. Volke is an authorized user on license #21-20030-01 (copies enclosed.)

Areas of Authorized Use

We have enclosed diagrams of decay in storage disposal facilities at both Bi-County and Riverside hospitals as well as an Exercise Stress Lab for Riverside Hospital to be added as areas of authorized use.

ALARA Program

We have enclosed an updated ALARA Program to conform with 10 CFR 20.

Radioactive Material Package Opening

We have enclosed an updated Radioactive Material Package Opening procedure.

In accordance with 10 CFR 170 we have enclosed a check payable to the U.S. Nuclear Regulatory Commission in the amount of $440.00 an an amendment fee.

We look forward to our amendment. If you have any questions, please contact our Radiation Safety Officer, Mr. Richard Nelson, at (810) 759-7320.

Sincerely,

M. I. Opipari DO

Michael I. Opipari, D.O.
Vice President/Chief Medical Officer

Enclosures

cc: T. Kumpuris
D. Nelson


Radioactive
Decay in
Storage Rm.
Locked Door
Riverside
Osteopathic
Hospital
ER
Driveway
Maintenance
Storage
Area
N
Hospital Emergency Room


Outside
Equip Room
Treadmills
Riverside Osteopathic Hospital
Third Floor Exercise Stress Lab
Outside
Elevator to
Nuclear Medicine

MAINTAINING OCCUPATIONAL RADIATION EXPOSURES ALARA

Item 10.1

1. Management Commitment

a. We, the management of this medical facility, are committed to the program described herein for keeping individual and collective doses as low as is reasonably achievable (ALARA). In accord with this commitment, we hereby describe an administrative organization for radiation safety and will develop the necessary written policy, procedures, and instructions to foster the ALARA concept within our facility. The organization will include a Radiation Safety Officer (RSO) and Radiation Safety Committee (RSC).

b. We will perform a formal annual review of the radiation safety program, including ALARA considerations. This will include reviews of operating procedures and past dose records, inspections, etc., and consultations with the radiation safety staff or outside consultants.

c. Modifications to operating and maintenance procedures and to equipment and facilities will be made if they will reduce exposures unless the cost, in our judgment, is considered to be unjustified. We will be able to demonstrate, if necessary, that improvements have been sought, that modifications have been considered, and that they have been implemented when reasonable. If modifications have been recommended but not implemented, we will be prepared to describe the reasons for not implementing them.

d. In addition to maintaining doses to individuals as far below the limits as is reasonably achievable, the sum of the doses received by all exposed individuals will also be maintained at the lowest practicable level. It would not be desirable, for example, to hold the highest doses to individuals to some fraction of the applicable limit if this involved exposing additional people and significantly increasing the sum of radiation doses received by all involved individuals.

Item 10.1 Cont'd.

2. Radiation Safety Committee / Officer

a. Review of Proposed Users and Uses

(1) The RSC will thoroughly review the qualifications of each applicant with respect to the types and quantities of materials and methods of use for which application has been made to ensure that the applicant will be able to take appropriate measures to maintain exposure ALARA.

(2) When considering a new use of byproduct material, the RSC will review the efforts of the applicant to maintain exposures ALARA.

(3) The RSC will ensure that the users justify their procedures and that individual and collective doses will be ALARA.

b. Delegation of Authority

(1) The RSO will have the authority of enforcement of the ALARA concept.

(2) The management will support the RSO and RSC when it is necessary for the RSO to assert authority. If management or the RSC has overruled the RSO, it will record the basis for its actions in the minutes of the quarterly meeting.

c. Review of ALARA Program

(1) The RSC will encourage all users to review current procedures and develop new procedures as appropriate to implement the ALARA concept.

(2) The RSC will perform a quarterly review of occupational radiation exposure with particular attention to instances in which the investigational levels in Table I are exceeded. The principal purpose of this review is to assess trends in occupational exposure as an index of the ALARA program quality and to decide if action is warranted when investigational levels are exceeded.

Item 10.1 Cont'd.

TABLE I: INVESTIGATIONAL LEVELS

	Body Part Exposed	Level I (mrems per calendar quarter)	Level II (mrems per calendar quarter)
1.	Whole body; head and trunk; active blood forming organs; or gonads.	125	375
2.	Hands and forearms; feet and ankles. Skin of whole body.	1250	3750
3.	Lens of the eye.	375	1125

(3) The RSC will evaluate our facilities overall efforts for maintaining doses ALARA on an annual basis. This review will include the efforts of the RSO, authorized users, and workers as well as those of management.

d. Annual and Quarterly Review

(1) Annual review of Radiation Safety Program. The RSO will perform an annual review of the radiation safety program for adherence to ALARA concepts.

(2) Quarterly review of Occupational Exposures. The RSO will review at least quarterly the external radiation doses of authorized users and workers to determine that their doses are ALARA in accordance with this program. A summary report will be prepared for the RSC.

(3) Quarterly review of Records of Radiation Surveys. The RSO will review radiation surveys of unrestricted and restricted areas to determine that dose rates and amounts of contamination were at ALARA levels during the previous quarter. A summary report will be prepared for the RSC.

Item 10.1 Cont'd.

e. Education Responsibilities for the ALARA Program

(1) The RSO will schedule briefings and educational sessions to inform workers of ALARA program efforts.

(2) The RSC will ensure that authorized users, workers, and ancillary personnel who may be exposed to radiation will be instructed in the ALARA philosophy and informed that management, and the RSO are committed to implementing the ALARA concept.

f. Cooperative Efforts for Development of ALARA Procedures

Radiation workers will be given opportunities to participate in formulating the procedures that they will be required to followed.

(1) The RSO will be in close contact with all users and workers in order to develop ALARA procedures for working with radioactive materials.

(2) The RSO will establish procedures for receiving and evaluating the suggestions of individual workers for improving health physics practices and will encourage the use of those procedures.

g. Reviewing Instances of Deviation from Good ALARA Practices

The RSO will investigate all known instances of deviation from good ALARA practices and, if possible, will determine the causes. When the cause is known, the RSO will implement changes in the program to maintain doses ALARA.

3. Authorized Users

a. New Methods of Use Involving Potential Radiation Doses

(1) The authorized user will consult with the RSO during the planning stage before using radioactive materials for new uses.

(2) The authorized user will review each planned use of radioactive materials to ensure that doses will be kept ALARA.

Item 10.1 Cont'd.

b. Authorized User's Responsibility to Supervised Individuals

(1) The authorized user will explain the ALARA concept and the need to maintain exposures ALARA to all supervised individuals.

(2) The authorized user will ensure that supervised individuals who are subject to occupational radiation exposure are trained and educated in good health physics practices and in maintaining exposures ALARA.

4. Individuals Who Receive Occupational Radiation Doses

a. Workers will be instructed in the ALARA concept and its relationship to work procedures and work conditions.

b. Workers will be instructed in recourses available if they feel that ALARA in not being promoted on the job.

5. Establishment of Investigational Levels in Order to Monitor Individual Occupational External Radiation Doses

This facility hereby establishes investigational levels for occupational external radiation doses which, when exceeded will initiate review or investigation by the RSO. The investigational levels that we have adopted are listed in Table 1. These levels apply to the exposure of individual workers.

The RSO will review form NRC-5, "Current Occupational External Radiation Exposures" or an equivalent form (e.g., dosimeter processor's report) results of personnel monitoring not less than once in any calendar quarter. The following actions will be taken at the investigational levels as stated in Table 1.

a. Personnel dose less than Investigational Level I.

Except when deemed appropriate by the RSO, no further action will be taken in those cases where an individual's dose is less than Table 1 values for the Investigational Level I.

b. Personnel dose equal to or greater than Investigational Level I but less than Investigational Level II.

Item 10.1 Cont'd.

The RSO will review the dose of each individual whose quarterly dose equals or exceeds Investigational Level I and will report the results to management and the RSC following the quarter when the dose was recorded. If the dose does not equal or exceed Investigational Level II, no action related specifically to the exposure is required unless deemed appropriate by management. The management will, however, review each such dose in comparison with those of others performing similar tasks as an index of ALARA program quality and will record the review.

c. Personnel dose equal to or greater than Investigational Level II.

The RSO will investigate in a timely manner the causes of all personnel doses equaling or exceeding Investigational Level II and, if warranted, will take action. A report of the investigation, any actions taken, and a copy of the individual's NRC Form-5 or its equivalent will be presented to management following completion of the investigation. The details of these reports will be filed by the RSO and reported to the RSC.

d Re-establishment of investigational Levels to levels above those listed in Table 1.

In cases where a worker or group of workers' doses need to exceed an investigational level, a new, higher investigational level may be established for that individual or group on the basis that it is consistent with good ALARA practices. Justification for new investigational levels will be documented by the RSO.

6. Signature of Certifying Officer

I hereby certify that this institution has implemented the ALARA Program set forth above.

M. I. Opipari DO

Signature

Michael I. Opipari, D.O.

Name (Print or Type)

Vice President/
Chief Medical Officer

Title

7/10/96

PROCEDURES FOR OPENING PACKAGES CONTAINING RADIOACTIVE MATERIAL

Item 10.6

1. Put on gloves to prevent hand contamination.

2. Visually inspect the package for any sign of damage (e.g., wet or crushed). If damage is noted, stop and notify the RSO.

3. Measure and record the exposure rate from the package at 1 meter ~~and at the package surface~~. If the rate is greater than 10 mR/hr, stop and immediately notify the RSO, the final delivery carrier and by telephone and fax the regional office of the NRC.

4. Measure and record the exposure rate on the surface of the package in the same orientation as the data taken in step 3 above. If greater than 200 mR/hr stop the procedure and immediately notify the RSO, the final delivery carrier and by telephone and fax the regional office of the NRC.

5. Wipe the external surface of the package in compliance with 10 CFR 20.1906. Assay the wipe sample with a suitable instrument sufficient to detect 2000 dpm/100 cm^2 to determine if there is any removable activity. If there is any contamination in excess of 22 dpm/cm^2, immediately notify the RSO, the final delivery carrier and by telephone and fax the regional office of the NRC.

6. Follow the steps listed below when opening the package.
   a. Remove the packing slip.
   b. Open the outer package following the supplier's instructions, if available.
   c. Open the inner package and verify that the contents agree with the packing slip.
   d. Check the integrity of the final source container. Look for broken seals or vials, loss of liquid, condensation, or discoloration of the packing material.
   e. If anything unusual is noticed, stop and notify the RSO.

7. Verify that the material received is the material ordered.

Item 10.6 Cont'd.

8. Monitor the packing material and the empty packages for contamination with a GM survey meter before discarding. If contaminated, treat as radioactive waste. If not contaminated, deface all radiation labels before discarding.

9. Record the receipt and all readings taken.

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Amy Lum Tobin D.O.	Michigan

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING: CLOCK HOURS IN LECTURE OR LABORATORY	TYPE AND LENGTH OF TRAINING: CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	William Beaumont Hospital Royal Oak, MI Dept. of Nuclear Medicine	8	2
b. RADIATION PROTECTION	same	4	2
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	same	2	2
d. RADIATION BIOLOGY	same	2	2
e. RADIOPHARMACEUTICAL CHEMISTRY	same (4/96 - 5/96)	2	2

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
Sr-89	1 - 2	William Beaumont Hospital	1	Bone Mets
I-131	125	Royal Oak, MI	2	Thyroid Ca
I-131	10	Dept of Nuclear Medicine	3	Hyperthyroidism
Tc-99m			150	Imaging
Tl-201			0	Imaging
In-111			2	Imaging

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT — U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Amy Lum Tobin D.O.

STREET ADDRESS: 14049 E 13 Mile Rd

CITY | STATE | ZIP CODE: Warren, MI 48093

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1. Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
2. Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
3. Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
	Thyroid scan	20	
	Thyroid uptake	10	
	Lung perfusion scan	20	
	Xenon ventilation study		
	Aerosol ventilation scan	20	
	Renal flow scan	10	
	Brain scan	8	
	Liver/spleen scan	3	
	Bone scan	30	
	Gastroesophageal study		
	LeVeen shunt study		
	Cystogram	2	
	Dacryocystogram		
	Cardiac perfusion scan.	40	
	Cardiac stress ventriculogram	22	
	Cardiac rest ventriculogram	10	
	Gallium scan		

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER
Amy Lum Tobin D.O.

PRECEPTOR STATEMENT *(Continued)*

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN *(Continued)*

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted or duplicated on separate sheet.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	2	
	TREATMENT OF HYPERTHYROIDISM	6	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR	4	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	4	
Other Sr-89	Bone mets	1	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
William Beaumont Hospital Royal Oak, MI Dept. of Nuclear Medicine	4/96 - 5/96	320

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR
Howard J. Dworkin, M.D.

b. NAME OF INSTITUTION
W. Beaumont Hospital

c. MAILING ADDRESS
3601 W. 13 Mile Rd

d. CITY
Royal Oak

e. MATERIALS LICENSE NUMBER(S)
21-01333-01

5. PRECEPTOR'S SIGNATURE
Howard J. Dworkin M.D.

7. PRECEPTOR'S NAME (Please type or print)
Howard J. Dworkin, M.D.

8. DATE
September 20, 1996

EXHIBIT 2

SUPPLEMENT A

SUPPLEMENT — U.S. NUCLEAR REGULATORY COMMISSION

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF PROPOSED AUTHORIZED USER OR RADIATION SAFETY OFFICER	2. FOR PHYSICIANS, STATE OR TERRITORY WHERE LICENSED
Amy Lum Tobin D.O.	Michigan

3. CERTIFICATION

SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING: CLOCK HOURS IN LECTURE OR LABORATORY	TYPE AND LENGTH OF TRAINING: CLOCK HOURS OF SUPERVISED ON-THE-JOB EXPERIENCE
a. RADIATION PHYSICS AND INSTRUMENTATION	Endocrinology & Nuclear Medicine Fellowship BiCounty Hospital Warren, MI		15
b. RADIATION PROTECTION	same		150
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	same		15
d. RADIATION BIOLOGY	same		15
e. RADIOPHARMACEUTICAL CHEMISTRY	same (8/94 - 8/96)	5	5

5. EXPERIENCE WITH RADIATION. *(Actual use of Radioisotopes or Equivalent Experience)*

ISOTOPE	mCi USED AT ONE TIME	LOCATION	CLOCK HOURS	TYPE OF USE
I-131	150	BiCounty Hospital Warren, MI	120	Hyperthyroidism & Thyroid Cancer therapy
Tc-99m	30	same	700	Imaging
Tl-201	4	same	300	Imaging
Xe-133	20	same	40	Imaging
Ga-67	5	same	5	Imaging

EXHIBIT 3

SUPPLEMENT B

SUPPLEMENT — U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. PROPOSED PHYSICIAN USER'S NAME AND ADDRESS

FULL NAME: Amy Lum Tobin DO,

STREET ADDRESS: 14049 13 Mile Rd

CITY: Warren | STATE: MI | ZIP CODE: 48093

KEY TO COLUMN C

PERSONAL PARTICIPATION SHOULD CONSIST OF:

1-Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.

2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.

3-Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
	Thyroid scan	910	
	Thyroid uptake	820	
	Lung perfusion scan	78	
	Xenon ventilation study	78	
	Aerosol ventilation scan		
	Renal flow scan	10	
	Brain scan	2	
	Liver/spleen scan	15	
	Bone scan	310	
	Gastroesophageal study		
	LeVeen shunt study		
	Cystogram		
	Decrydcystogram		
	Cardiac perfusion scan.	210	
	Cardiac stress ventriculogram		
	Cardiac rest ventriculogram	20	
	Gallium scan	0	

EXHIBIT 3 (Continued)

PROPOSED PHYSICIAN USER

PRECEPTOR STATEMENT *(Continued)*

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN *(Continued)*

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS *(Additional information or comments may be submitted in duplicate on separate sheets.)* D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	20	
	TREATMENT OF HYPERTHYROIDISM	160	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS		
Other			

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

LOCATION	DATES	CLOCK HOURS OF EXPERIENCE
Endocrindex and Nuclear Medicine Fellowship - Bicounty Hospital, Warren, MI	8/94 - 8/96	750

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR: Nancy J. Andrews D.O.

b. NAME OF INSTITUTION: Bicounty Community Hospital

c. MAILING ADDRESS: 12355 E. Ten Mile Rd.

d. CITY: Warren, MI 48089-2065

e. MATERIALS LICENSE NUMBER(S): 21-04082-01

5. PRECEPTOR'S SIGNATURE

Nancy J. Andrews D.O.

7. PRECEPTOR'S NAME *(Please type or print)*

Nancy J. Andrews D.O.

8. DATE

9/26/96

Amy Lum Tobin, D.O.
6935 Heather Heath Lane
West Bloomfield, MI. 48322
810-932-7132

EDUCATION:

'86 - '90 — **Doctor of Osteopathy**
Michigan State University
East Lansing, MI

'82 - '84 — **Bachelor's Degree, Medical Technology**
Oakland University
Rochester, MI

'79 - '81 — **Associate's Degree, Medical Laboratory Technician**
Oakland Community Hospital
Waterford, MI

'77 - '78 — **Undergraduate Work**
Michigan State University
East Lansing, MI

POST GRADUATE TRAINING:

7/94 - 8/96 — **Endocrinology Fellowship**
Bi-County Community Hospital
Warren, MI.

7/91 - 6/94 — **Internal Medicine Residency**
Botsford General Hospital
Farmington Hills, MI.

7/90 - 6/91 — **Transitional Year**
Botsford General Hospital
Farmington Hills, MI.

CERTIFICATIONS:

1994 — American Osteopathic Board of Internal Medicine

Current — BCLS, ACLS

REFERENCES:

Will be furnished upon request

JOHN ENGLER
GOVERNOR

STATE OF MICHIGAN
DEPARTMENT OF COMMERCE

H 565391

BOARD OF PHARMACY

CONTROLLED SUBSTANCE LICENSE

*THIS LICENSE VALID ONLY IF PROFESSIONAL LICENSE IS ACTIVE

AMY LUM TOBIN
6935 HEATHER HEATH LANE
WEST BLOOMFIELD MI 48322

ENDORSEMENT NO.	EXPIRATION DATE	
5101010948	12/31/97	2960195

THIS DOCUMENT IS ISSUED UNDER THE LAWS OF THE STATE OF MICHIGAN

JOHN ENGLER
GOVERNOR

STATE OF MICHIGAN
DEPARTMENT OF COMMERCE

H 565390

BOARD OF OSTEOPATHIC MEDICINE AND SURGERY

PHYSICIAN
LICENSE

AMY LUM TOBIN
6935 HEATHER HEATH LANE
WEST BLOOMFIELD MI 48322

ENDORSEMENT NO.	EXPIRATION DATE	
5101010948	12/31/97	2960194

THIS DOCUMENT IS ISSUED UNDER THE LAWS OF THE STATE OF MICHIGAN

CONTROLLED SUBSTANCES REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON, D.C. 20537

The Controlled Substances Act of 1970 reads in part as follows:

Sec. 304. (a) A registration pursuant to Section 303 to manufacture, distribute, or dispense a controlled substance may be suspended or revoked by the Attorney General upon a finding that the registrant:

(1) has materially falsified any application filed pursuant to or required by this title or Title II,

(2) has been convicted of a felony under this title or Title III or any other law of the United States, or of any State, relating to any substance defined in this title as a controlled substance; or

(3) has had his State license or registration suspended, revoked, or denied by competent State authority and is no longer authorized by State law to engage in the manufacturing, distribution, or dispensing of controlled substances.

FOR REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
BL2681626	03-31-97	$216.00

SCHEDULES	BUSINESS ACTIVITY	DATE ISSUED
2,2N,3,3N,5	PRACTITIONER	03-26-94

LUM, AMY C
BETSFORD GENERAL HOSPITAL
28050 GRAND RIVER
FARMINGTON HILLS, MI 48024

FORM DEA-223 (5/88)

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, BUSINESS ACTIVITY, OR VALID AFTER THE EXPIRATION DATE.

NRC FORM 374 (10-89) U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 2 PAGES

Amendment No. 44

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) and at the place(s) designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Michigan Hospital and Medical Center	In accordance with letter dated January 19, 1990 3. License number 21-03835-01 is amended in its entirety to read as follows:
2. 2700 Martin Luther King Jr. Blvd. Detroit, MI 48208	4. Expiration date June 30, 1995
	5. Docket or Reference No 030-02033

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed
C. Any byproduct material identified in 10 CFR 31.11	C. Prepackaged Kits	C. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

C. In vitro studies.

CONDITIONS

10. Locations of Use: 2700 Martin Luther King, Jr. Blvd., Detroit, Michigan; 9221 E. Jefferson Avenue, Detroit, Michigan and 2255 Fort Street, Lincoln Park, Michigan.

. Radiation Safety Officer: Frank J. Messana, D.O.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
21-03835-01

Docket or Reference number
030-02033

Amendment No. 44

12. Authorized Users:

A. Frank J. Messana, D.O., for material in 10 CFR 35.100, 35.200, 35.500 and 31.11.

B. Paul A. Garber, D.O., for material in 10 CFR 35.100, 35.200, 35.500 and 31.11.

C. Steven M. Lewin, D.O., for material in 10 CFR 35.100, 35.200, 35.500 and 31.11.

D. Saleem Azad, M.D., for material in 10 CFR 35.100, 35.200, 35.500 and 31.11.

E. Benson Selitsky, D.O., for material in 10 CFR 35.100, 35.200, 35.500 and 31.11.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

14. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. The licensee shall maintain records of information important to safe and effective decommissioning at 2700 Martin Luther King Jr. Boulevard, Detroit, Michigan per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

16. This license is based on the licensee's statements and representations listed below:

A. Applications dated January 19, 1990 and April 2, 1990; and

B. Letters dated April 23, 1990 (with attachments), May 1, 1990 (with attachments), October 21, 1991, January 7, 1992 (with attachments), January 10, 1992 (signed by Bruce A. Pruden), January 10, 1992 (signed by Patricia Kennedy-Scott) and October 15, 1994.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date December 2, 1994

By _____
Materials Licensing Section, Region III

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 07

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Southgate Radiology	In accordance with letter dated June 8, 1993 3. License number 21-20030-01 is amended in its entirety to read as follows:
2. 15300 Trenton Road Southgate, MI 48195	4. Expiration date March 31, 1996
	5. Docket or Reference No. 030-17665

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

B. Medical use described in 10 CFR 35.200.

CONDITIONS

10. Location of Use: 153 Trenton Road, Southgate, Michigan

11. Radiation Safety Officer: Dennis Vollman, D.O.

12. Authorized Users:

A. Dennis Vollman, D.O., for material in 10 CFR 35.100 and 35.200.

B. Norberto A. Sugayan, M.D., for material in 10 CFR 35.100 and 35.200.

COPY 5

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
21-20030-01

Docket or Reference number
030-17665

Amendment No. 07

12. (Continued)

C. Karla Volke, D.O., for material in 35.100 and 35.200.

D. John N. Paesano, D.O., for material in 10 CFR 35.100 and 35.200.

E. Lisa Ribons, D.O., for material in 10 CFR 35.100 and 35.200.

13. The licensee shall maintain records of information important to safe and effective decommissioning at 15300 Trenton Road, Southgate, Michigan per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

14. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

15 This license is based on the licensee's statements and representations listed below:

A. Letters dated January 22, 1991 and June 6, 1991.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date August 23, 1993

By Patricia M. Vachuska
Materials Licensing Section, Region III

COPY

UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555-0001

May 6, 1996

SOUTHGATE RADIOLOGY
ATTN: DR. VOLLMAN, DENNIS P., D.O.
Radiation Safety Officer
NUCLEAR MEDICINE AND ULTRASOUND
15300 TRENTON ROAD
SOUTHGATE, MI 48195

SUBJECT: ONE-TIME EXTENSION OF LICENSE EXPIRATION DATE
LICENSE NUMBER 21-20030-01, DOCKET NUMBER 3017665

Dear DR. VOLLMAN, DENNIS P., D.O.

On January 16, 1996, the Nuclear Regulatory Commission (NRC) amended its regulations in 10 CFR 30, 40, and 70 to extend the expiration date of certain byproduct, source, and special nuclear material licenses by five years (61 FR 1109). The above referenced license was extended by this rulemaking and will now expire on March 31, 2001. Your license will not be amended to show this extended date until the next routine licensing action. Until then, you may provide copies of this letter to vendors and other interested parties as evidence that the license has been extended as a result of the rule.

The extended license authorizes the same activities and contains the same limitations as it previously did. There will be no change in the frequency that the NRC inspects activities authorized by this license.

The amended rules state that in the case of licensees who are granted extensions and who have a currently pending renewal application for that extended license, the application will be considered withdrawn by the licensee and any renewal fees paid by the licensee for that application will be refunded. This will apply to licenses with expiration dates after July 1, 1995, for which renewal applications and the appropriate fees have been submitted and the renewal is still pending. Refunds will be mailed to licensees under separate cover.

All licensees, including those whose renewal applications were withdrawn by this rulemaking, who wish to change their radiation safety programs must request amendment of their licenses to reflect these changes. Amendment requests must include the correct amendment fee since the NRC cannot apply pending renewal refund balances toward amendment fees.

If you have any questions regarding this letter, please contact the individual below.

John R. Madera, Division of Nuclear Materials Safety - (708) 829-9834

Thank you for your cooperation in this matter.

Sincerely,

Donald A. Cool, Director
Division of Industrial and Medical Nuclear Safety
Office of Nuclear Materials Safety and Safeguards

JAN 17 1997

Richard Nelson, CNMT
Radiation Safety Officer
Detroit Osteopathic Hospital Corp.
Central Offices
P.O. box 5153
26100 American Drive
Southfield, MI 48086-5153

Dear Mr. Nelson:

Enclosed is Amendment No. 97 to your NRC Material License No. 21-04082-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please note: we have added five years to the expiration date listed on your license. You have received official notification from our headquarters office explaining the cause for the five year extension. In the meantime, if you have any questions, please call me.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

302069

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

4. Request and obtain a license amendment before you:

   a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

   b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;

   c. Change Radiation Safety Officers;

   d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

   e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

   f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements,

prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Loren J. Hueter
Nuclear Materials Licensing Branch

License No.: 21-04082-01
Docket No.: 030-02042

Enclosures: 1. Amendment No. 97
2. NRC Form 313

DOCUMENT NAME: M:\03002042.CL7
To receive a copy of this document, indicate in the box: "C" = Copy without attachment/enclosure "E" = Copy with attachment/enclosure "N" = No copy

OFFICE	DNMS/RIII	N							
NAME	LHUETER:jaw								
DATE	01/16/97								

OFFICIAL RECORD COPY

CONVERSATION RECORD

TIME

DATE 1-13-97

O VISIT O CONFERENCE Ø TELEPHONE

O INCOMING
Q OUTGOING

NAME OF PERSON(S) CONTACTED OR IN CONTACT | ORGANIZATION (OFFICE, DEPT. ETC.) | TELEPHONE NO.

Richard Nelson CNMT, RSO | Detroit osteopathic Hosp. Corp at Bi-County Community Hosp. | 810-759-7320

SUBJECT

CN 302069

SUMMARY

Diagram of "decay-in-storage" facility at Bi County hospital was not enclosed with amend. application dated 11-18-96
Mr Nelson agreed to FAX a copy to me

ACTION REQUIRED

NAME OF PERSON DOCUMENTING CONVERSATION | SIGNATURE | DATE

Lorna Hunter | 1-13-97

ACTION TAKEN

SIGNATURE | TITLE | DATE

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
801 WARRENVILLE ROAD
LISLE, ILLINOIS 60532-4351

November 27, 1996

Richard P. Nelson, CNMT
Radiation Safety Officer
Detroit Osteopathic Hospital Corporation
P. O. Box 5153
26100 American Drive
Southfield, MI 48086-5153

SUBJECT: ACKNOWLEDGEMENT OF CORRESPONDENCE
(Letter Dated 11/18/96)

Dear Licensee:

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

___ New License X Amendment ___ Renewal
___ Termination ___ Auth User (Amendment not required)
___ Other_____

No administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-3 below, as applicable).

1. New and amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.

2. Renewal actions are normally processed within 180 days, however, under timely filing (before expiration), you may continue to operate under your existing license.

3. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

A copy of your correspondence has been forwarded to our Licensing Fee and Debt Collection Branch (301/415-6097) for approval of the fee category and amount, if required.

If you have a compelling safety or business-related reason for requesting expedited review, please contact the Materials Licensing Branch at (630) 829-9887. We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number.

Nuclear Materials Support Branch

Mail Control No. 302069
License No. 21-04082-01